Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SOPHiA GENETICS (SOPH) EBIT Margin (2020 - 2025)

SOPHiA GENETICS's EBIT Margin history spans 6 years, with the latest figure at 85.3% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 1307.0% to 85.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 91.76%, a 1038.0% increase, with the full-year FY2025 number at 91.76%, up 1038.0% from a year prior.
  • EBIT Margin hit 85.3% in Q4 2025 for SOPHiA GENETICS, up from 91.78% in the prior quarter.
  • Over the last five years, EBIT Margin for SOPH hit a ceiling of 85.3% in Q4 2025 and a floor of 230.37% in Q1 2022.
  • Historically, EBIT Margin has averaged 135.83% across 5 years, with a median of 115.78% in 2024.
  • Biggest five-year swings in EBIT Margin: crashed -7380bps in 2022 and later surged 10147bps in 2023.
  • Tracing SOPH's EBIT Margin over 5 years: stood at 192.09% in 2021, then surged by 41bps to 112.69% in 2022, then rose by 1bps to 111.13% in 2023, then rose by 11bps to 98.37% in 2024, then grew by 13bps to 85.3% in 2025.
  • Business Quant data shows EBIT Margin for SOPH at 85.3% in Q4 2025, 91.78% in Q3 2025, and 100.92% in Q2 2025.